Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort

• Main Authors: Marloes E. van Muijen (Author), Sarah E. Thomas (Author), Hans M.M. Groenewoud (Author), Marisol E. Otero (Author), Paul M. Ossenkoppele (Author), Marcellus D. Njoo (Author), Sharon R.P. Dodemont (Author), Else N. Kop (Author), Maartje A.M. Berends (Author), Marjolein I.A. Koetsier (Author), Johannes M. Mommers (Author), John E.M. Körver (Author), Ron A. Tupker (Author), Marjolein S. de Bruin-Weller (Author), Lizelotte J.M.T. Weppner-Parren (Author), Bas Peters (Author), Marloes M. Kleinpenning (Author), Astrid L.A. Kuijpers (Author), W. Peter Arnold (Author), Paula P.M. van Lümig (Author), Juul M.P.A. van den Reek (Author), Elke M.G.J. de Jong (Author)
• Format: Book
• Published: Medical Journals Sweden, 2022-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Real-world evidence, directly comparing the effectiveness of interleukin (IL)17-inhibitors, IL23-inhibitors, tumour necrosis factor alpha (TNF-α)-inhibitors and an IL12/23-inhibitor in psoriasis, is scarce. The aim of this study was to directly compare the first-year effectiveness of biologic therap...